---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-019467"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T21:40:45.036265+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Apogee reports positive interim Phase 1 APG990 data with ~60-day half-life; 2024 net loss $182.1M

## Summary
- APG990 demonstrated ~60-day half-life, supporting every 3- and 6-month maintenance dosing; well tolerated up to 1,200 mg.
- Combination APG279 (APG777+APG990) Phase 1b vs. DUPIXENT planned for 2025, readout expected H2 2026.
- Full-year 2024 net loss $182.1M (vs. $84.0M in 2023); cash, equivalents and marketable securities $731.1M, runway into Q1 2028.
- Phase 2 APEX trial for APG777 in atopic dermatitis over-enrolled Part A, Part B initiated; 16-week top-line data expected mid-2025.
- R&D expenses $167.9M (up from $68.4M) driven by pipeline advancement and personnel costs.

## SEC filing metadata
- accession: 0001104659-25-019467
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465925019467/0001104659-25-019467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465925019467/tm258007d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-019467
- JSON: https://secwatch.observer/filing/0001104659-25-019467.json
- Plain text: https://secwatch.observer/filing/0001104659-25-019467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.